Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis
{{output}}
Background: Anti-CD20 monoclonal antibodies are now a common first-line treatment for multiple sclerosis (MS). Rituximab, ocrelizumab and ofatumumab have all been associated with a dose-dependent risk of hypogammaglobulinaemia, b... ...
